Hydroxychloroquine Dosing and Titration
For rheumatologic conditions, hydroxychloroquine should be dosed at ≤5.0 mg/kg based on actual body weight per day, with typical dosing of 200-400 mg daily, and no titration is required—start at the target maintenance dose. 1, 2
Standard Dosing by Indication
Rheumatoid Arthritis
- Initial dose: 400-600 mg daily (single dose or divided twice daily)
- Maintenance dose: 200-400 mg daily after several weeks to months once therapeutic effect achieved 2
- The drug has cumulative action requiring weeks to months for maximum effect—there is no need for gradual titration
Systemic Lupus Erythematosus and Chronic Discoid Lupus
- Standard dose: 200-400 mg daily (single dose or divided twice daily) 2
- Most patients achieve prolonged remission with stable doses of 200 mg/day (approximately 3.0-3.5 mg/kg/day) 3
Critical Dosing Principle: Weight-Based Calculation
The most important safety consideration is keeping the daily dose below 5.0 mg/kg of actual (real) body weight. 1, 4 This recommendation represents a major shift from older guidelines that used ideal body weight, which resulted in overdosing thin patients and created confusion in obese patients.
Why Real Weight Matters
The 2016 landmark study of 2,361 patients demonstrated that:
- Doses of 4.0-5.0 mg/kg real weight had <1% toxicity risk in first 5 years and <2% risk up to 10 years 1
- Risk increases sharply to ~20% after 20 years even at recommended doses 1
- Doses >5.0 mg/kg dramatically increase retinopathy risk to 10% after 10 years 4
- Very thin patients are at increased risk when ideal weight calculations are used 1
Special Consideration for Obese Patients
For severely obese patients, cap the daily dose at 400 mg regardless of weight calculation 5. Evidence shows that 27% of hydroxychloroquine retinopathy cases in obese women occurred despite "safe" dosing by 2016 guidelines 6. For women with BMI ≥30 kg/m², consider using the older 6.5 mg/kg ideal weight threshold as it may be safer 6.
Practical Dosing Examples
For a 70 kg patient: Maximum daily dose = 350 mg
- Practical approach: 200 mg in morning, 200 mg in evening (400 mg total is acceptable and commonly used)
For a 50 kg patient: Maximum daily dose = 250 mg
- Practical approach: 200 mg daily, or alternate 200 mg and 400 mg on different days to average appropriate dose
For a 100 kg severely obese patient: Cap at 400 mg daily regardless of weight
Dose Adjustments for Risk Factors
Renal Disease (Most Important Risk Factor)
Patients with reduced glomerular filtration rate (CKD stage ≥3) require lower doses and closer monitoring 1, 4. Renal impairment increases circulating drug levels unpredictably, as hydroxychloroquine is cleared primarily by the kidney. These patients have 2.3-fold higher odds of supratherapeutic blood levels 7.
Concomitant Tamoxifen Use
This increases retinopathy risk and may warrant lower HCQ doses or more frequent screening 1
Older Age at Initiation
Starting HCQ at older age increases risk, though this is a weaker factor than dose and duration 5
Blood Level Monitoring (Emerging Evidence)
Recent data suggests therapeutic reference range of 750-1150 ng/mL 7:
- Levels ≥1150 ng/mL associated with 2.1-fold higher toxicity odds and represent supratherapeutic dosing 7
- Blood level monitoring may optimize dosing, particularly in patients with CKD stage ≥3 7
- However, blood level testing is not yet widely available and shows high inter-individual variability 1
Administration Details
- Take with food or milk to minimize gastrointestinal side effects 2
- Do not crush or divide tablets 2
- Dosing can be split (e.g., 200 mg twice daily) or given once daily
- For intermediate doses, split tablets or eliminate doses on certain days of the week—blood levels stabilize over weeks so variable dosing averages out 1
Common Pitfalls to Avoid
Using ideal body weight instead of actual weight for dose calculation—this overdoses thin patients 1
Exceeding 5 mg/kg/day in average-weight patients or 400 mg/day in obese patients—this dramatically increases retinopathy risk 1, 4, 2
Failing to adjust dose in renal disease—these patients need lower doses due to reduced clearance 1, 4
Attempting gradual titration—unnecessary as the drug has cumulative action over weeks to months; start at target maintenance dose 2
Stopping HCQ for borderline screening findings without confirmation—the goal of screening is to safely maintain this valuable medication as long as possible 1